Aveo, Astellas ending Tivozanib deal, colon-cancer work halted

|By:, SA News Editor

Aveo Oncology (AVEO) and Japan's Astellas Pharma (ALPMF) are ending their agreement to develop Aveo's lead drug Tivozanib and they will halt a Phase II study testing its use in colon cancer.

The move comes after Aveo said in January that it would end a similar-stage trial of Tivozanib as a treatment for breast cancer because of poor enrollments. In July, the drug was rejected as a treatment for kidney cancer because of inconsistent study results.